Utah Retirement Systems’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Utah Retirement Systems’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,500	Closed	-$726K	–	1004
2025 Q1	$726K	Hold	5,500	–	–	0.01%	709
2024 Q4	$459K	Hold	5,500	–	–	0.01%	789
2024 Q3	$402K	Hold	5,500	–	–	﹤0.01%	806
2024 Q2	$377K	Buy	+5,500	New	+$381K	﹤0.01%	828

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Utah Retirement Systems's ITCI Position: Q2 2025 in Review

Utah Retirement Systems sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,500 shares — an estimated $726K sold.

Utah Retirement Systems first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $726K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Utah Retirement Systems reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Utah Retirement Systems sold 5,500 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $726K.
Utah Retirement Systems first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Utah Retirement Systems's Intra-Cellular Therapies Inc. position peaked at $726K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Utah Retirement Systems's 13F filing for Q2 2025, filed 14 Aug 2025.